SCHEMBL6926705

SCHEMBL6926705

CCN(CC)CCOc1cccc2c1c1cccc(Cl)c1n2Cc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
ESR1 P03372 3/20 0.42
ESR2 Q92731 2/20 0.42
KDM4E B2RXH2 3/20 0.40
PLA2G2A P14555 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
DRD2 P14416 2/20 0.37
DRD3 P35462 2/20 0.37
DRD1 P21728 1/20 0.37
POLB P06746 1/20 0.36
MCL1 Q07820 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BIRC5 O15392 1/20 0.36
P2RX7 Q99572 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MEN1 O00255 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925172 0.92 TP53 (0.47) TP53MAPTESR1ESR2KDM4E
SCHEMBL6921487 0.91 ESR1 (0.43) TP53MAPTESR1ESR2KDM4E
SCHEMBL6927305 0.90 ESR1 (0.42) TP53MAPTESR1ESR2KDM4E
SCHEMBL6924339 0.84 DRD2 (0.46) TP53MAPTESR1ESR2KDM4E
SCHEMBL6920875 0.84 MEN1 (0.43) TP53MAPTESR1ESR2PLA2G2A
SCHEMBL6924574 0.84 ESR1 (0.41) TP53MAPTESR1ESR2PLA2G2A
SCHEMBL6924126 0.82 ESR1 (0.43) TP53MAPTESR1ESR2KDM4E
SCHEMBL6924596 0.81 DRD2 (0.49) TP53MAPTESR1ESR2KDM4E
SCHEMBL6927241 0.79 DRD2 (0.51) TP53MAPTESR1ESR2KDM4E
SCHEMBL7505287 0.79 ESR1 (0.44) MAPTESR1ESR2KDM4EPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US claimed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP claimed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO claimed
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US disclosed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP disclosed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO disclosed